A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Trial Profile

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary) ; Doxorubicin; Paclitaxel; Topotecan
  • Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms COCOS
  • Most Recent Events

    • 19 Jun 2017 Status changed from recruiting to suspended due to Scheduled Interim Monitoring.
    • 08 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 11 Jan 2016 Planned initiation date changed from 1 Sep 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top